New Pre-Clinical Data for Iclaprim

Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017™

https://globenewswire.com/news-release/2017/10/06/1142163/0/en/Motif-Bio-Presents-New-Pre-Clinical-Data-for-Iclaprim-at-IDWeek-2017.html

1. Pre-Clinical Data Support the Potential Use of Iclaprim in the Treatment of Staphylococcus aureus Pneumonia in Cystic Continue reading New Pre-Clinical Data for Iclaprim

New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’

http://markets.businessinsider.com/news/stocks/New-Nitric-Oxide-Treatment-Eradicates-Emerging-Superbugs-1002996746

Novoclem Therapeutics, a biotech company focused on advancing nitric oxide therapies for the treatment of respiratory diseases, today announced that data from an in vitro study with Continue reading New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’

Presentation of Positive New Data from Studies of VIBATIV at ASM Microbe

https://www.streetinsider.com/dr/news.php?id=12977909&gfv=1

Theravance Biopharma (TBPH) Announces Presentation of Positive New Data from Studies of VIBATIV at ASM Microbe

Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma” or the “Company”) today announced the presentation of positive new data from Continue reading Presentation of Positive New Data from Studies of VIBATIV at ASM Microbe

New antibiotic could treat superbugs

http://www.medicalnewstoday.com/releases/315898.php

New antibiotic from bacteria found on Kenyan ant could help beat MRSA

A new antibiotic, produced by bacteria found on a species of African ant, is very potent against antibiotic-resistant ‘superbugs’ like MRSAaccording to scientists.

Researchers at the University of East Anglia (UEA) and the John Innes Centre (JIC) discovered a new member of the Streptomyces bacteria family, isolated from the African fungus-growing plant-ant Tetraponera penzigi. They have named the new species Streptomyces formicae and the antibiotics formicamycins, after the Latin formica, meaning ant.

Lab tests have shown these new antibiotics are effective against methicillin resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE), bacteria which are resistant to a number of common antibiotics and can cause life-threatening infections.

Almost all of the antibiotics currently in clinical use come from a group of bacteria called actinomycetes that were isolated from soil between 40-80 years ago, the ‘golden age’ of antibiotic discovery. Inappropriate use of these antibiotics since then has led to widespread antimicrobial resistance (AMR), where disease-causing bacteria and fungi have become resistant to one or more antibiotics.

Prof Matt Hutchings from UEA said: “We have been exploring the chemical ecology of protective symbioses formed between antibiotic-producing bacteria and fungus-growing insects to better understand how these associations are formed and explore them as a new source of anti-infective drugs.

“Kenyan plant-ants live in symbiosis with thorny acacia trees. They live and breed in domatia – which are hollowed out structures which the plant evolved to house them – and grow fungus in them for food. In return, they protect the plants from large herbivores including elephants, which won’t eat plants covered in ants.”

The team isolated a number of actinomycete bacterial strains from the acacia plant housing the ants, selecting a number for genome sequencing. One particular strain caught their attention, and the antibiotic compounds produced from it showed promising activity in early tests against other disease-causing bacteria.

Prof Hutchings said: “We tested formicamycins against clinical isolates of MRSA and vancomycin-resistant Enteroccocus faecium (VRE) and found that they are very potent inhibitors of these organisms.”

To test this further, they repeated the tests by growing the strains for 20 generations in very low, sub-inhibitory concentrations of formicamycins and found no sign that the test strains acquired spontaneous higher level resistance to the new antibiotics.

Prof Wilkinson from JIC said: “Our findings highlight the importance of searching as-yet under-explored environments, which, when combined with recent advances in genome sequencing and editing, enables the discovery of new species making natural product antibiotics which could prove invaluable in the fight against AMR.”

Article: Formicamycins, antibacterial polyketides produced by Streptomyces formicae isolated from African Tetraponera plant-ants, Zhiwei Qin, John T Munnoch, Rebecca Devine, Neil A Holmes, Ryan Seipke, Karl A Wilkinson, Barrie Wilkinson and Matthew Hutchings , Chemical Science, doi: 10.1039/C6SC04265A, published online 13 February 2017.

Austin Biotech Savara Nets $20M in Series C for Phase 3 Study

Xconomy Texas Austin — A year after releasing results from a Phase 2 clinical trial, Savara Pharmaceuticals has announced $20 million in Series C funding that it will use to take its inhaled version of an antibiotic to Phase 3.

Continue reading Austin Biotech Savara Nets $20M in Series C for Phase 3 Study

New therapeutic options for respiratory tract infections.

PURPOSE OF REVIEW:
The progressive increase of respiratory tract infections caused by multidrug-resistant organisms (MDROs) has been associated with delays in the prescription of an adequate antibiotic treatment and increased mortality, Continue reading New therapeutic options for respiratory tract infections.

Why Do Some Infections Persist? Blame Bacterial Socialism, Says New Study

http://www.newswise.com/articles/why-do-some-infections-persist-blame-bacterial-socialism-says-new-study

New research to be published January 13 in the journal Scientific Reports shows that some bacterial cultures adopt an all-for-one/one-for-all strategy that would make a socialist proud Continue reading Why Do Some Infections Persist? Blame Bacterial Socialism, Says New Study

Garlic Extract Could Help Cystic Fibrosis Patients Fight Infection

A chemical found in garlic can kill bacteria that cause life-threatening lung infections in people with cystic fibrosis, research suggests. The study is the first to show that the chemical, known as allicin, could be an effective treatment against a group of infectious bacteria that is highly resistant Continue reading Garlic Extract Could Help Cystic Fibrosis Patients Fight Infection

Savara Pharmaceuticals Raises $10 Million to Advance AeroVanc for MRSA Lung Infection in People with Cystic Fibrosis

Company Completes Enrollment in Phase 2 Clinical Trial

Austin, TX – October 6, 2014 – Savara Pharmaceuticals announced today that it closed a $10 million bridge financing round to support the  development of AeroVanc, the first inhaled antibiotic Continue reading Savara Pharmaceuticals Raises $10 Million to Advance AeroVanc for MRSA Lung Infection in People with Cystic Fibrosis